Herceptini   Marketing

Herceptini trastuzumab is a Gentech proprietary first-in-market humanised monoclonal antibody (mAb).  It targets an oncogene human epidermal growth factor receptor 2 (HER2) gene which our scientists identified.   This cancer profile is termed the HER2+ subtype.  Extremely high specificity, a novel engineered mAb and the first mAb to target an oncogene which can deliver better patient outcomes than monoclonal chemotherapy therapy are the basis of Herceptini trastuzumab’s strategic advantage and value proposition.  This is a greenfield therapy and there is no competitor.

​

Herceptini trastuzumab targets key catalytic kinase human epidermal growth factor receptor 2 (HER2+) in early-stage and metastatic subtype breast cancer, which is more aggressive and faster-growing than other subtypes.  Overexpression of HER2+ brings increased homodimerization and heterodimerization that leads to a stronger pro-tumorigenic signalling cascade and expedites the growth of breast cancer cells. 

​

Current cancer treatment of HER2+ cancer includes a combination of surgery to remove the tumour, radiation therapy to reduce the risk of recurrence and chemotherapy to kill cancer cells.   Chemotherapy treatment has toxic side effects and a lower survival rate than other subtypes of breast cancers. Successful clinical trial results have shown that Herceptini trastuzumab combined with chemotherapy as the first line of treatment is able to deliver superior patient outcomes than chemotherapy monotherapy.    Significant improvements are in overall response rate, longer duration of response, 20% reduction in risk of death, time to disease progression and time to treatment failure.     Moreover, there is only a marginal difference in the incidence and severity of adverse events comparatively.